We investigated the effects of treatment with the TLR4 agonist LPS, which upregulates TLR4 expression, and the M2-CM treatment to elucidate the role of TLR4 in HCC cell malignancy [11, 16, 17]. The gene discussed is TLR4; the disease is hepatocellular carcinoma.